Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical

Page created by Troy Mendez
 
CONTINUE READING
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
Investor Presentation
   TSX: TMD / OTCQX: TITXF

       May 2016
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
Forward Looking Statements
 This presentation contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations,
 technological development and implementation, performance and business prospects, opportunities, and illustrations and prototypes of the SPORT™ Surgical Systems.
 Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate" and similar expressions have been used to
 identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently
 available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results,
 performance, achievements or technological development and implementation to be materially different from any future results, performance, achievements or
 technological development and implementation that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the
 "Risk Factors" section of the Company's Annual Information Form in respect of the fiscal year ended December 31, 2015 and other information contained in the
 Company’s public filings (which may be viewed at www.sedar.com). Information contained in this presentation is qualified in its entirety by such public filings. Should
 one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or
 achievements may vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered
 carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the
 presentation are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results,
 performance or achievements will be consistent with these forward-looking statements. This presentation does not constitute an offer to sell any class of securities of the
 Company in any jurisdiction.

                                                                                                                                                                               /   PG 2
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
Co mp an y Ov erv iew
Titan Medical is…
the designer and developer of SPORT™, a highly versatile single incision advanced

surgical system that significantly expands the addressable market for single and multi-

quadrant abdominal surgeries performed on a robotic platform. The System is designed to

provide superior clinical capabilities and unparalleled OR efficiency at operating costs similar

to traditional laparoscopic surgery.

                                                                                          /   PG 3
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
Co mp an y Ov erv iew
Investment Considerations
•   Addressing market opportunity for robotic surgery valued at $20 billion* by 2021

•   Highly versatile single incision advanced surgical technology including 13 patents and 30 patent
    applications pending

•   Substantial benefits to patient, surgeon and hospital versus competitive offerings

•   More features, more OR flexibility, lower cost, improved economics versus da Vinci®

•   Highly experienced management team with significant track record of success

•   Attractive business model; expect 510(k) submission in the second half of 2017**

    * Source: WinterGreen Research Report 2014
    ** Last reported in Titan MD&A filed May 16, 2016                                                  /   PG 4
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
Co mp an y Ov erv iew
Robotic Surgery Market Opportunity

Total market opportunity for
 robotic surgery valued at
        $20 billion

                                     /   PG 5
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
Bu sin ess Ov erv iew
        $10B Capital Revenue Opportunity
                                       US HOSPITALS FOR ROBOTIC SYSTEMS
                                                 da Vinci Penetration          Available Market

              ~ 10,500 Placement Opportunities
            with $10B Capital Revenue Potential                                   (1)

                                                                                                                     6000

                                                                  3500
                           1000

                           1000
                                                                     0                                                0
            P RI M A RY   A N D S E CON D A RY                 T E RT I A RY                      A M BU LA T OR Y   S U RG E RY   CE N T E RS

                                                                                                                                                 /   PG 6
(1) $950K per system and on average, 1 system per hospital
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
Bu sin ess Ov erv iew
$3.75B in Annual Recurring Revenue
        $3,000,000,000

        $2,500,000,000                                                       ~ 2.5M Available
                                                                                 Procedures
                                                                            with $2.7B Procedure
        $2,000,000,000                                                      Revenue Potential (2)
                                ~ 10,500 Placement
                                   Opportunities          $2,700,000,000
        $1,500,000,000          with $1.05B Service
                                Revenue Potential (1)
        $1,000,000,000

                                     $1,050,000,000
         $500,000,000

                   $0
                                     Service Revneue    Procedure Revenue
  (1)     $100K of Annual Service Revenue                                                           /   PG 7
  (2)     $1075 per procedure revenue
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
SPORT™ Mark et Ov erv iew
Evolution of Surgical Care
                                                                                                                           SPORT
                                                                                                                    - A premier solution
                                                                                   Robotic Surgery                    that will transform
   Open Surgery                                              MIS                                                      the challenges facing
                                                                              - Further expands upon the benefits
                                                                                of MIS                                robotics today
 - Broad application                   - Minimally Invasive Surgery
                                           (“MIS”) has been a growing trend                                         - Will be significantly
 - Requires significant                                                       - Robotic procedures have grown
                                           over the past 25 years                                                     more affordable, agile
     hospital stay and                                                          from 1,000 procedures in 2000 to
                                                                                650,000* in 2015                      and versatile as
     recovery time                     - Reduced hospitalization time
                                                                                                                      compared to existing
 - Significant risk of                 - Reduced risk of adverse events       - However, most robots are
                                                                                                                      robotic solutions
     adverse events                                                             expensive and have procedural
                                       - Requires highly skilled surgeons
                                                                                and operational limitations

                                                                                                                                  /    PG 8
  * Source: Intuitive Surgical Earnings Call Transcript for Q4 2015
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
SPORT™ Pro d u ct Ov erv iew
Today’s Robotic Surgery Environment
  To mitigate the downside of MIS and improve surgical care of patient outcomes, robotic technology
  was introduced to the operating room:

             Benefits                                                            Challenges
   - Better Dexterity                               - High Cost of Entry                         - Reduced Operational Efficiency-
                                                                                                    Long Setup Time
   - Improved 3D Visualization                      - Huge Footprint
                                                                                                 - Low ROI for Hospitals
   - Improved Ergonomics                            - High Level of Training
                                                                                                 - Limited Procedural Capability
                                                    - Increased Cost For Each Case

  Last year only 650,000 surgeries out of a possible 4,000,000 were done using a robot…

 “Proven technology is easily replaced by same or better if it provides a greater ROI--clinically, financially
 and operationally”
 - Rand A. Ballard, Chief Commercial Officer, Vizient Inc. (New VHA, MedAssets, Novation and UHS Combined Entity)          /   PG 9
Investor Presentation - May 2016 TSX: TMD / OTCQX: TITXF - Titan Medical
SPORT™ Mark et Ov erv iew
SPORT: Benefits
 Benefits to Patient               Benefits to Surgeon                       Benefits to Hospital

 - Less Pain                       - Improved Visualization with 3D Vision   - Decreased Length of Hospital Stay

 - Quicker Recovery                - Improved Dexterity With Multi-          - Increased Patient Satisfaction
                                      Articulating Instruments
 - Fewer and Smaller Scars                                                   - Potentially Longer Operating Careers of
                                   - Easier and Shorter Learning Curve         Surgeons
 - Shorter Hospital Stay
                                   - Improved Precision                      - Increased Surgical Case Volume
 - Reduced Blood Loss
                                   - Improved Ergonomics                     - Employee Participation and Retention
 - Reduced Risk of Infection
                                   - Automation of Tasks and Subtasks        - Improved ROI- Clinically, Financially, and
                                                                               Operationally

 “A surgeon could use SPORT for every abdominal operation!”
 - David Larson, Chief of Colorectal Surgery, Mayo Clinic, Rochester, MN
                                                                                                                /   PG 10
SPORT: Robotic Surgery Optimized
                                                                                                        Single-Arm Mobile
                                                                                                           Patient Cart
                       Open 3D High
                   Definition Visualization

                                              Camera Insertion Tube
                                              with Self-Cleaning Lens
Ergonomic Mobile
  Workstation

                      Natural Multi-articulated
                      Handle Control Interface
                                                                        Multi-articulated Instruments
                                                                          with Replaceable Tips

                                                                                                             /   PG 11
SPORT™ Pro d u ct Ov erv iew
SPORT Workstation
             - Highly Ergonomic Design

             - Natural Multi-articulated Handle Interface with
               Proximity Finger Sensors

             - Open Un-obtrusive 3D High Definition
               Platform with 32-inch Flat-screen Monitor

             - Multi-configurable Elbow Resting and Pedal
               Positioning Feature

             - Adjunct Touchscreen LCD monitor that can
               interface to hospital information systems,
               including PACS for images

             - Swiveling Easy Gliding Coasters
                                                                 /   PG 12
SPORT™ Ov erv iew
SPORT Patient Cart
 - Single-arm configuration

 - Mobile, compact, transportation capability

 - Easy to maneuver and position Central Unit

 - Easy to load and unload Camera Insertion Tube
   (CIT) and Instrument Interface

 - Single cable for easy cable management

                                                   /   PG 13
SPORT™ Pro d u ct Ov erv iew
SPORT CIT and Instruments
            - Camera Insertion Tube (CIT) accommodates 2
              multi-articulated instruments with self-cleaning
              dual channel camera

            - 10 Multi-Articulated Multi-Use instruments with
              Single-Use Replaceable Tips

            - Monopolar, Bipolar, Vessel Sealing and Clip
              Applier capabilities

            - Multi-quadrant access

                                                                 /   PG 14
SPORT in Actio n
SPORT in Action

                  /   PG 15
SPORT™ Mark et Ov erv iew
Intellectual Property
     The SPORT system is a single incision robotic surgical system that has been
           developed from the ground up with a unique technical footprint

              Patents & Patent Applications                     Licensed Technology

              - 11 U.S. Patents                                 - 2 U.S. Patent

              - 27 Patent Applications                          - 3 Patent Applications (US, EP)
                 (PCT, US, EP, CA, CN, JP, IN)

      The Company anticipates expanding its patent portfolio by filing patent applications as it
      progresses in the development of robotic surgical technologies and by licensing suitable
                                                 technologies

                                                                                                   /   PG 16
SPORT™ Mark et Ov erv iew
Competition
                       Critical Features for Robotic Surgery                                           SPORT™            daVinci®   SurgiBOT™   Alf-X™
 Multi-Articulated Instruments
 3D High Definition Visualization
 Natural Handle Control (left is left, right is right, up is up and down is down)
 Ergonomic Surgeon Workstation or Console
 Needle Driver/ Graspers/ Monopolar / Bipolar / Advanced Instruments
 Dual Channel Endoscope for High-caliber 3-D
 Mobile, Low Profile Footprint with Minimal Cables (Ease of Transportation)
 Ease of Setup (single arm is easy, having multiple arms is complex)
 Quick and Easy Intraoperative Multi Quadrant Access
 New Tips for each procedure (No compromise on instrument performance)
 Open, Non-isolated Display (Surgeon always has direct view of OR table)
 Scope Lens-washing Capability (Minimal scope cleaning adds to efficiency)
 Tool or Eye tracking Camera Movement (Least disruptive to procedural flow)

                                                                                                                                                         PG 17

                                         Source: Product Information from Intuitive Surgical and TransEnterix websites
SPORT™ Mark et Ov erv iew
SPORT vs da Vinci® - Hospital Savings Per Procedure

                                                                         SPORT™        daVinci®
     System Cost                                                         ~$950,000   ~$1,800,000 (1)
     No. of Cases Amortized Over (7 years at 150 per year)                 1,050         1,050
     Amortized Robot Cost Per Case                                         $905         $1,714
     Instrument and Accessory Cost Per Case                               $1,075        $1,835
     Annual Service Agreement (10% of System Cost)                        $95,000      $180,000
     Amortization Period (150 cases)                                        150           150
     Cost of Service Agreement Per Case                                    $634         $1,200
     Estimated Cost Per Procedure                                         $2,614        $4,749

   (1)   Initial cost of daVinci will vary based on features purchased

                                                                                                       /   PG 18
Bu sin ess Ov erv iew
Rated Top 5 at GPO Technology Expo!
      Example - Med Assets – New Technology Meeting

            -   One of the largest GPOs – 4,500 acute care members
            -   200+ applicants – Only 88 selected
            -   420 committee members (representing 200 healthcare systems)
                reviewed new technologies and rated them on a scale of 1-5 in 5
                key areas:
                  -   Innovative technology
                  -   Improves quality of care at my facility
                  -   Improves efficiencies at my facility

                  -   Meets a need in healthcare
                  -   Ready to purchase
                                                                                  /   PG 19
SAGES March 2016
 Voice of Customer – SAGES and AORN
                                                “I see this as a potential in most of my bariatric patients….”

                                                “Out of all the robotic platforms I’ve seen, this is the best
                                                design and has the most potential….”

“You have to create a sense of organization around robotic surgery to
understand that the robotic system is a total program, not a piece of
technology.”

“Proven technology is easily replaced by same or better if it provides a
greater ROI--clinically, financially and operationally”
                                                                                                          /     PG 20
Milestones
Remaining Development Milestones
 •   Initiate usability study – 1H 2016

 •   Complete usability study – 2H 2016

 •   Optimization trials – 1H 2017

 •   System design freeze – 1H 2017

 •   Build design verification units / Initial audit for CE mark – 2H 2017

 •   Complete design verification and validation – 2H 2017

 •   Final CE mark audit – 2H 2017

 •   Submit 510 (k) application to FDA – 2H 2017
Bu sin ess Ov erv iew
Titan Medical: Clinical Adoption Strategy

  -   Develop clinical support – Regional Centers of
      Excellence by Specialty

  -   Develop executive support – Executive Champions
      Network for Execution Guidance
  -   Deliver “ROI” to support the program investment
      for Healthcare Institutions
  -   Train, support and service our customers

                                                        /   PG 22
Summary
Financial Snapshot                                                 TMD (TSX), TITXF (OTCQX)

     Share price (TMD)                           $0.78 (As of May 24, 2016)
     Shares outstanding                          145.4 million FD*

     Management ownership (3/31/16)              4.48%

     Cash, cash equivalents (3/31/16)            $12 million

*Fully diluted includes, under the Treasury Stock method, an additional 3,453,055 options with a weighted-average exercise price of
CDN $1.32, as well as common shares issued as result of the public offering, November 16, 2015 and the private placement of
November 23, 2015.

                                                                                                                    /   PG 23
Summary
Summary
•   Addressing market opportunity for robotic surgery valued at $20 billion by 2021

•   Highly versatile single incision advanced surgical technology including 13 patents and 30 patent
    applications pending

•   Substantial benefits to patient, surgeon and hospital versus competitive offerings

•   More features, more OR flexibility, lower cost, improved economics versus da Vinci®

•   Highly experienced management team with significant track record of success

•   Attractive business model; expect 510(k) submission in the second half of 2017

                                                                                                       /   PG 24
Thank You
TSX: TMD / OTCQX: TITXF
Co mp an y Ov erv iew
Management Team
     John Hargrove, Chairman & CEO
             -    40 years of executive-level health care experience
             -    Vice President of Corporate Accounts, Johnson & Johnson; President, Corporate Account Management, Ohmeda Inc.
             -    B.A. from the University of Georgia

     Dr. Reiza Rayman MD, PhD, President
             -    Collaborated in the world’s first robotic beating heart cardiac bypass surgery in September 1999
             -    Entrenched researcher on all available robotic platforms, Active practitioner with over 400 robotic surgeries under belt
             -    M.D. from Univ of Toronto and Ph.D. in Telesurgery from Univ of Western Ontario; M.Sc. In Fluid Dynamics from Univ of Western Ontario,

     Stephen Randall, CFO
             -    +19 years of Executive level experience
             -    Extensive experience in accounting, finance, capital markets, tax planning, compliance, IT management, mergers/acquisitions and operations
             -    CPA, CGA, B. Comm

     Dr. Dennis Fowler MD, MPH, Executive Vice President, Clinical and Regulatory Affairs
             -    Co-inventor of the single-incision Insertable Robotic Effector Platform (IREP) technology licensed from Columbia University to Titan Medical

             -    Certified by the American Board of Surgery; Formerly the Gerald and Janet Carrus Professor of Surgical Science, Director of the Center for Innovation and
                  Outcomes Research in the Department of Surgery, Columbia University College of Physicians and Surgeons                                    /    PG 26
             -    MD from University of Kansas School of Medicine, Master in Public Health from Columbia University
Commercial Leadership Team

                                                                                                                                                                     Co mp an y Ov erv iew
     Sachin Sankholkar, Vice President, Marketing
             -    +15 Years of Robotic Device Development, Launch and Marketing Experience at Intuitive Surgical, +19 Years of Med Device Experience
             -    Exceptional Surgeon Network and KOL Development Expertise in GYN, Urology, General, Colorectal and Bariatric Surgery.
             -    M.B.A. in Marketing and General Management at USC Marshall School of Business, M.S. in Biomedical Engineering at Drexel University

     Paige Hargrove, Vice President, WW Sales
             -    +8 Years of Robotic Sales and Management Experience at Intuitive Surgical and Stereotaxis, +11 Years of Tenure at J&J
             -    Years of track record with team building, strategic planning, training, customer retention and business development
             -    BA, Bloomsburg University of Pennsylvania

     Chris Seibert, Vice President, Corporate Accounts
             -    +10 Years of Robotic Sales and Management Experience at Intuitive Surgical and Stereotaxis, +12 Years of total Med Device Experience
             -    Entrenched IDN/GPO sales channel expertise and C-level access/network within top GPOs/IDNs
             -    MBA at University of South Alabama; MA at University of Oklahoma; BA at University of Alabama.

     Frederic Nahon, Vice President, Sales EMEA and Asia
             -    + 12 Years of Capital/Clinical Sales Management Experience at Intuitive Surgical, Stereotaxis and Imacor
             -    Sergeant Major in the French Army;
             -    OR Chief, Hospital Jean Prince, Tahiti, French Polynesia.
                                                                                                                                                         /   PG 27
You can also read